Proteomic biomarkers for overall and progression‐free survival in ovarian cancer patients

Purpose: To determine if the level of apolipoprotein A1, hepcidin, transferrin, inter‐α trypsin IV internal fragment, transthyretin (TT), connective‐tissue activating protein 3 (CTAP3), serum amyloid A1, β‐2 microglobulin (B2M) might have impact on overall and progression‐free survival for ovarian cancer (OC) patients.

[1]  E. Fung,et al.  Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis , 2010, Proteomics. Clinical applications.

[2]  Jing Li,et al.  Discovery and identification of potential biomarkers of pediatric Acute Lymphoblastic Leukemia , 2009, Proteome Science.

[3]  Qun Zhao,et al.  [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]. , 2008, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[4]  C. Yip,et al.  Lectin‐based electrophoretic analysis of the expression of the 35 kDa inter‐α‐trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies , 2008, Electrophoresis.

[5]  D. Swinkels,et al.  Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. , 2007, Clinical chemistry.

[6]  R. Bast,et al.  A large-scale multi-center independent validation study of a panel of seven biomarkers for the detection of ovarian cancer. , 2006, Journal of Clinical Oncology.

[7]  S. Tretli,et al.  Improved short‐term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[8]  Deborah Schrag,et al.  Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. , 2006, Journal of the National Cancer Institute.

[9]  E. D. de Vries,et al.  Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma , 2006, Cancer.

[10]  M. Tetsche,et al.  The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. , 2005, Gynecologic oncology.

[11]  Kym Faull,et al.  Characterization of serum biomarkers for detection of early stage ovarian cancer , 2005, Proteomics.

[12]  A. Vlahou,et al.  Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. , 2005, Oncology reports.

[13]  A. Proietto,et al.  Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Petricoin,et al.  Biomarkers of ovarian tumours. , 2004, European journal of cancer.

[15]  A. Jakobsen,et al.  Prognostic significance of p53, Her‐2, and EGFR overexpression in borderline and epithelial ovarian cancer , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[16]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[17]  Robert C. Bast,et al.  Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.

[18]  Jeffrey S. Morris,et al.  Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..

[19]  K. Kozak,et al.  Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[21]  E. S. Andersen,et al.  Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. , 2003, Gynecologic oncology.

[22]  T. Halvorsen,et al.  Survival and Prognostic Factors in Patients With Ovarian Cancer , 2003, Obstetrics and gynecology.

[23]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[24]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[25]  Tore Halvorsen,et al.  Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre‐operative diagnosis of pelvic masses , 1996, British journal of obstetrics and gynaecology.

[26]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[27]  J. Guastalla,et al.  [Advanced ovarian cancer]. , 1995, Soins; la revue de reference infirmiere.

[28]  D. Oram,et al.  A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer , 1991, British journal of obstetrics and gynaecology.

[29]  K. McGlynn,et al.  Prognostic importance of serum transferrin and ferritin in childhood Hodgkin's disease , 1990, Cancer.

[30]  Amanda Graham,et al.  The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. , 2008, International journal of oncology.

[31]  Z. Hernádi,et al.  [Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer]. , 1992, Zentralblatt fur Gynakologie.

[32]  D.,et al.  Regression Models and Life-Tables , 2022 .